Sunlenca

Active substance

Lenacapavir

Holder

Gilead Sciences Belgium B.V.

Status

closed

Indication

in combination with other antiretroviral(s), for the treatment of adults with multidrug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen.

Public documents

Approbation

Information for the patient

Informed consent

Last update

04/09/2025